Restrictions Eased on Bariatric Surgery Due to GLP-1 Costs

Source link :

Amid rising concern about the potential long-term costs of using glucagon-like peptide 1 (GLP-1) agonists to treat obesity, some insurers are making access to bariatric surgery easier. While the relationship may not be entirely causal, data do suggest that at least for now, these new agents for treating obesity including semaglutide (Wegovy) and tirzepatide (Zepbound) […]

Author : News Health

Publish date : 2024-03-21 12:14:17

Copyright for syndicated content belongs to the linked Source.